Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | ACACA | Q13085 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640329 | 1.00 | CACNA1H (0.52) | CACNA1HKDM4EPKMMAPK14ACACB | |
| SCHEMBL6642459 | 0.89 | KDM4E (0.58) | KDM4EPKMMAPK14ACACBACACA | |
| SCHEMBL6637593 | 0.89 | KDM4E (0.58) | KDM4EPKMMAPK14ACACBACACA | |
| SCHEMBL6637597 | 0.89 | KDM4E (0.58) | KDM4EPKMMAPK14ACACBACACA | |
| SCHEMBL6638918 | 0.87 | ACACB (0.55) | KDM4EPKMMAPK14ACACBACACA | |
| SCHEMBL6638926 | 0.87 | ACACB (0.55) | KDM4EPKMMAPK14ACACBACACA | |
| SCHEMBL6458829 | 0.84 | ACACB (0.47) | KDM4EPKMMAPK14ACACBACACA | |
| SCHEMBL6638634 | 0.82 | KDM4E (0.56) | KDM4EPKMACACBACACADRD2 | |
| SCHEMBL24512806 | 0.82 | NPC1 (0.60) | KMT2AKDM1AMAOBHDAC6 | |
| SCHEMBL4167585 | 0.82 | NPC1 (0.60) | KMT2AKDM1AMAOBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | CACNA1H 4079/4885KDM4E 4784/4885PKM 2387/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | CACNA1H 4422/4885KDM4E 4752/4885PKM 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.